Skip to main content

Table 2 Association of survival after sunitinib therapy and the best objective response on target lesions

From: The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

Best objective response on target lesions Progression-free survival Overall survival
Median survial (months) 1-year (%) 3-years (%) Median survial (months) 1-year (%) 3-years (%)
All cases 8.9 35 15 23.5 81 35
CR/PR 15.0 50 40 59.7 90 68
SD 9.2 41 23 24.2 81 38
PD 6.8 27 17 17.1 63 0
NE 2.2 10 0 18.1 60 10
  1. IQR interquaterile range; CR complete response; PR pertial response; SD stable disease; PD progressive disease; NE not evaluated
  2. Estimated with Kaplan–Meier method